Skip to content

Perineural Injection Therapy for Ulnar Neuropathy at Elbow

The Long-term Effect for Perineural Injection Therapy for Ulnar Neuropathy at Elbow

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02986906
Enrollment
36
Registered
2016-12-08
Start date
2017-03-01
Completion date
2019-10-30
Last updated
2019-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulnar Neuropathy at Elbow

Keywords

ulnar neuropathy at elbow, Dextrose, perineural injection

Brief summary

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy. Although many conservative managements of UNE, the effectiveness of these methods are unsatisfied especial the moderate degree of UNE. Recently, ultrasound-guided perineural injection therapy (PIT) with 5% dextrose is progressively applicated for clinical treatment for entrapment neuropathy. However, current studies have not proved the effects of PIT on peripheral neuropathy because these studies enrolled small number of patients and lacked controlled design. We design a randomized, double-blind, controlled trail to assess the effect after ultrasound-guided PIT with 5% dextrose in patients with mild and moderate UNE.

Detailed description

After obtaining written informed consent, 40 patients, clinically diagnosed with mild or moderate UNE were randomized into intervention or control group. Participants in intervention group received one-session of ultrasound-guided PIT injection with 5cc. 5% dextrose and control group received 2cc 0.9% normal saline+3cc Triamcinolone (30mg) (total 5 cc) ultrasound-guided PIT injection. The primary outcome is Disabilities of the Arm, Shoulder and Hand (DASH) and secondary outcomes include visual analog scale (VAS), cross-sectional area (CSA) of the ulnar nerve, motor nerve conduction velocity of the ulnar nerve, and strength of palmer finger pinch and grasp. The evaluation was performed pretreatment as well as on the 1st, 3rd and 6th month after the treatment.

Interventions

Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve

DRUG2cc 0.9% normal saline+3cc Triamcinolone (30mg)

Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve

DEVICEUltrasound

The ultrasound was used for injection guidance

Sponsors

Tri-Service General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 20-80 year-old. * Diagnosis was confirmed using an electrophysiological study

Exclusion criteria

* Cancer * Coagulopathy * Pregnancy * Inflammation status * Cervical radiculopathy * Polyneuropathy, brachial plexopathy * Thoracic outlet syndrome * Previously undergone wrist surgery or steroid injection for ulnar neuropathy

Design outcomes

Primary

MeasureTime frameDescription
Change from pain on 1st, 3rd, 6th month after injectionPre-treatment, 1st, 3rd, 6th month after injectionDigital pain severity or paresthesia/dysthesia was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.

Secondary

MeasureTime frameDescription
Change from severity of symptoms and functional status on 1st, 3rd, 6th month after injectionPre-treatment, 1st, 3rd, 6th month after injectionTaiwan Disabilities of the Arm, Shoulder and Hand (DASH) contains 11-item disability/symptom scale and each item has five levels of response scoring from 1 to 5. The higher score means more disability or severer symptoms.
Change from nerve conduction velocity on 1st, 3rd, 6th month after injectionPre-treatment, 1st, 3rd, 6th month after injectionNerve motor conduction velocity of the ulnar nerve before treatment and multiple time frame after treatment.
Change from cross-sectional area on 1st, 3rd, 6th month after injectionPre-treatment, 1st, 3rd, 6th month after injectionUsing the musculoskeletal sonogram to measure the cross-sectional area of the ulnar nerve before treatment and multiple time frame after treatment.
Change from palmer finger pinch and grasp on 1st, 3rd, 6th month after injectionPre-treatment, 1st, 3rd, 6th month after injectionThe palmer finger pinch and grasp strength was measured using dynamometer (Fabrication Enterprises Inc., USA) before treatment and multiple time frame after treatment.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026